Fusion Pharmaceuticals reports progress across its pipeline of TATs

Fusion Pharmaceuticals reported continued progress across its pipeline of target alpha therapies and provided recent corporate highlights. Fusion CEO John Valliant, Ph.D., commented, "With three Phase 1 clinical programs developing TATs as next-generation radiopharmaceuticals, Fusion is leading a wave of excitement in the radiopharmaceutical sector. Fusion is poised for an exciting year, with data from the Phase 1 study of FPI-1434 in solid tumors expressing IGF-1R expected in the second quarter. Additionally, we expect to file an investigational new drug application for FPI-2068, our first novel TAT being developed in collaboration with AstraZeneca, in the first quarter of 2023. While advancing our clinical programs, we’ve continued to focus on ensuring adequate actinium supply, and recently announced a new partnership with established global medical isotope supplier BWXT Medical. We are well positioned to execute on our clinical programs and continue to advance a diversified pipeline of cancer therapies generated through Fusion’s internal R&D capabilities and technologies." Highlights: FPI-2068 IND expected to be submitted in the first quarter of 2023. FPI-1434 Phase 1 data expected in the second quarter of 2023. FPI-1966 Phase 1 study open and enrolling patients; Company expects to provide clinical data update in 2024. New actinium-225 partnership with BWXT Medical, a global leader in medical isotope supply, supports growing pipeline opportunities.